Navigation Links
Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
Date:2/23/2009

ic vaccines.

* www.who.int/vaccines-documents/DocsPDF06/863.pdf

About Live Attenuated Influenza Vaccine (LAIV)

Nobilon acquired in 2004 the majority of rights to develop, commercialize and manufacture the Live Attenuated Influenza Vaccines (LAIV), both egg- and cell culture-based, from Australian company BioDiem, which had acquired these rights from the Institute of Experimental Medicine in St. Petersburg, Russian Federation. The LAIV may offer several improvements over current vaccines such as single-dose intranasal spray delivery, improved convenience and earlier and broader protection, which is of particular interest in a pandemic situation. Nobilon is developing a cell culture-based LAIV for seasonal influenza and is currently preparing for the 'first-in-human' study with LAIV for seasonal influenza.

About the World Health Organization (WHO)

The World Health Organization was founded in 1948. WHO is a public international organization consisting of 193 Member States, and a specialized agency of the United Nations. WHO is the directing and coordinating authority on international health work, and promotes technical cooperation for health, carries out programs to control and eradicate disease and strives to improve the quality of human life.

About Nobilon

Nobilon International BV, a part of Schering-Plough Corporation, was founded in 2003 and was acquired through the Organon BioSciences acquisition in 2007. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines, building on existing expertise within Schering-Plough. Nobilon focuses on respiratory, traveler's and sexually transmitted infections. One of its core expertises is large-scale cell culture productio
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... May 21, 2013  The Lindsley F. Kimball Research Institute ... is a Grand Challenges Explorations winner, an initiative ... Dr. Sara Lustigman , Head of the ... and development research project, titled Innovative 3-D in ... are needed to screen drugs to help eliminate onchocerciasis (river ...
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2
... Augments Senior Management Team with Recent Strategic Hires ... ... May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced that ... for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia Consortium, ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
... 14 Campbell Alliance,the leading management consulting firm ... that Gary Tyson, Senior Vice,President of the firm,s ... the global rollout of electronic data capture (EDC),systems ... will be,held on May 28-29, 2008, at the ...
Cached Biology Technology:Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe 2Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe 3
(Date:5/21/2013)... world,s largest scientific society, invites news media coverage ... 8-12, 2013, in Indianapolis, Ind. It will take ... area hotels. , With more than 7,100 presentations ... from astronomy to zoology ― the meeting will ... assortment of spot news and feature possibilities. The ...
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... book designed for parents helps them better understand the ... fight them, while offering practical advice for preventing infections ... Your Kids: The Complete Guide to Protecting (without Overprotecting) ... Press, is the inside source on germ defense ...
... proteins have finally explained why computer models of proteins ... This work could have vast implications in bioengineering and ... between structure and function in these basic building blocks ... as the cover article of the Oct. 16 issue ...
... average price for all types of gasoline is holding ... at the pump might be short-lived as research from ... biggest hurdles to the wide-scale production of fuel cell-powered ... biomolecular engineering, led the research team in discovering a ...
Cached Biology News:Handbook helps parents deal with childhood infections 2Speed plays crucial role in breaking protein's H-bonds 2Speed plays crucial role in breaking protein's H-bonds 3Fuel cells gearing up to power auto industry 2Fuel cells gearing up to power auto industry 3
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known virus microRNAs ...
...
... is an excellent choice for supporting hydrocarbon processing. ... GC, this one-channel workhorse can double sample throughput ... one. You get all the capability and reliability ... instrument that has the same proven performance of ...
... GC-8A is Shimadzu's basic gas chromatograph model ... use, the GC-8A supports a single detector, ... injection port(s), and analog output. Isothermal or ... The GC-8A is only 17.3 inches (43.9 ...
Biology Products: